THE RUSSIANS ALSO HAVE A PFC PRODUCT--SAFE IN HUMANS!!!!
USE OF PERFTORAN IN TREATMENT OF SEVERE GASTROINTESTINAL
HEMORRHAGES
G.Safronov, E.Selivanov, M. Khanevich, A.Tikanadze, V.Verbitsky, S. Sudko, D.
Lazarenko
Russian Institute of Hematology and Transfusiology, TMO20, St.Petersburg, Russia
With introduction of infusion solutions having gas transport characteristics (Perftoran),
the problem of treatment of gastrointestinal hemorrhages associated with severe blood
losses, especially in the absence of satisfactory blood supply, came nearer to its
solution. We used Perftoran to treat 36 patients admitted to the clinic with a severe
bleedings from chronic ulcers of the stomach and duodenum and operated on without
delay. Perftoran was administered immediately after induction of anesthesia, the patients
being supplied simultaneously with oxygen through respiratory tract intubation. The dose
of Perftoran ranged from 450 to 1350 ml. Clinico-laboratory studies showed that
intravenous administration of Perftoran affected favourably the patients' condition. There
was an improvement in blood gas-transport function, acid-base state, and metabolic
processes in tissues. Perftoran also produced a beneficial effect on the central and
peripheral hemodynamics. There were no complications associated with Perftoran use.
At the same time. we managed to diminish almost twice the volume of erythrocyte
suspension transfused. Most efficacious was Perftoran when administered to elderly or
very old patients with drastic pathological changes in the cardiovascular and respiratory
systems, in the presence of hepatic and renal insufficiencies when blood transfusions can
result in vital organ and system decompensation and provoke thromboembolic
complications.
Next
Previous
Respond
|
